- Global Pharma News & Resources

Leap Therapeutics to Participate in the H.C. Wainwright 20th Annual Global Investment Conference

CAMBRIDGE, Mass., Aug. 30, 2018 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ : LPTX ), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. Mirabelli, Ph.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 20th Annual Global Investment Conference, being held in New York City on September 4-6, 2018.

Leap Presentation Details:

H.C. Wainwright 20th Annual Global Investment Conference

Date: Thursday, September 6, 2018

Time: 9:35 A.M.

The presentation will be webcast live and may be accessed on the Investors page of the company's website at, where a replay of the event will also be available for a limited time.

About Leap Therapeutics

Leap Therapeutics (NASDAQ : LPTX ) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric cancer, biliary tract cancer, and gynecologic cancers, with an emerging focus on patients with defined mutations of the Wnt pathway and in combination with immune checkpoint inhibitors. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in two advanced solid tumor studies. For more information about Leap Therapeutics, visit or our public filings with the SEC that are available via EDGAR at or via


This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements include statements relating to Leap's expectations with respect to the development and advancement of DKN-01, TRX518, and other programs, including the initiation, timing and design of future studies, enrollment in future studies, business development, and other future expectations, plans and prospects. Detailed information regarding factors that may cause actual results to differ materially will be included in Leap Therapeutics' periodic filings with the Securities and Exchange Commission (the "SEC"), including Leap Therapeutics' Form 10-K that Leap filed with the SEC on February 23, 2018. Any forward looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.


Douglas E. Onsi

Chief Financial Officer

Leap Therapeutics, Inc.


Argot Partners

Investor Relations

Heather Savelle or Mary Jenkins


Editor Details

Related Links

Last Updated: 31-Aug-2018